Race, ethnicity, ancestry, and pharmacogenetics

Mount Sinai Journal of Medicine

Volumn 77, Issue 2, 2010, Pages 133-139

  Urban, Thomas J ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Ethnicity; Genome wide association studies; Pharmacogenetics; Race

Indexed keywords

CYTOCHROME P450 2C9;

ARTICLE; DRUG RESPONSE; ETHNICITY; GENETIC ANALYSIS; GENETIC VARIABILITY; HEALTH DISPARITY; HUMAN; PHARMACOGENETICS; PLESIOMORPHY; RACE;

ARYL HYDROCARBON HYDROXYLASES; BIOMARKERS, PHARMACOLOGICAL; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77949835287     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20168     Document Type: Article

References (28)

1. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
2. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
3. Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation 2008; 118: 1383-1393.
4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982; 248: 2004-2011.
5. Muszkat M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin Pharmacol Ther 2007; 82: 215-218.
6. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 2006; 7: 1641-1648.
7. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10: 139-150.
8. Kim MJ, Huang SM, Meyer UA, et al. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 2009; 49: 138-146.
9. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
10. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 1986; 314: 1547-1552.
11. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-2057.
12. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5: 178-187.
13. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330-341.
14. Campbell CD, Ogburn EL, Lunetta KL, et al. Demonstrating stratification in a European American population. Nat Genet 2005; 37: 868-872.
15. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
16. Ledford H. Language: disputed definitions. Nature 2008; 455: 1023-1028.
17. Foster MW. Looking for race in all the wrong places: analyzing the lack of productivity in the ongoing debate about race and genetics. Hum Genet 2009; 126: 355-362.
18. Patten MA. 'Subspecies' and 'race' should not be used as synonyms. Nature 2009; 457: 147.
19. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360: 1696-1698.
20. Hirschhorn JN. Genomewide association studies-illuminating biologic pathways. N Engl JMed 2009; 360: 1699-1701.
21. Need AC, Goldstein DB. Next generation disparities in human genomics: concerns and remedies. Trends Genet 2009; 25: 489-494.
22. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
23. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
24. Sabeti PC, Varilly P, Fry B, et al. Genome-wide detection and characterization of positive selection in human populations. Nature 2007; 449: 913-918.
25. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
26. Itsara A, Cooper GM, Baker C, et al. Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet 2009; 84: 148-161.
27. Daly AK, Donaldson PT, Bhatnagar P, et al. HLAB* 5701 genotype is a major determinant of druginduced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
28. Cann HM, de Toma C, Cazes L, et al. A human genome diversity cell line panel. Science 2002; 296: 261-262.